This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goldstein, E. J. C.
Right arrow Articles by Fernandez, H. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goldstein, E. J. C.
Right arrow Articles by Fernandez, H. T.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2006, p. 2875-2879, Vol. 50, No. 8
0066-4804/06/$08.00+0     doi:10.1128/AAC.00286-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.

In Vitro Activities of Dalbavancin and 12 Other Agents against 329 Aerobic and Anaerobic Gram-Positive Isolates Recovered from Diabetic Foot Infections

Ellie J. C. Goldstein,1,2* Diane M. Citron,1 Yumi A. Warren,1 Kerin L. Tyrrell,1 C. Vreni Merriam,1 and Helen T. Fernandez1

R. M. Alden Research Laboratory, Santa Monica, California 90404,1 David Geffen School of Medicine at UCLA, Los Angeles, California 900732

Received 6 March 2006/ Returned for modification 5 April 2006/ Accepted 3 May 2006

Tests of dalbavancin's in vitro activity against 209 aerobic and 120 anaerobic isolates from pretreatment diabetic foot infections showed an MIC90 of ≤0.125 µg/ml against methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-resistant S. aureus (MRSA), and 120 anaerobes (Clostridium perfringens, other clostridia, Peptoniphilus asaccharolyticus, Finegoldia magna, and Anaerococcus prevotii), compared to respective MIC90s for MSSA and MRSA of 0.5 and 1 µg/ml for vancomycin, 4 and 4 µg/ml for linezolid, 0.5 and 0.5 µg/ml for daptomycin, and 0.25 and >8 µg/ml for clindamycin.

* Corresponding author. Mailing address: Alden Research Laboratory, 2021 Santa Monica Blvd., no. 740 East, Santa Monica, CA 90404. Phone: (310) 315-1511. Fax: (310) 315-3662. E-mail: ejcgmd{at}aol.com.

Antimicrobial Agents and Chemotherapy, August 2006, p. 2875-2879, Vol. 50, No. 8
0066-4804/06/$08.00+0     doi:10.1128/AAC.00286-06
Copyright © 2006, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Liu, C.-Y., Huang, Y.-T., Liao, C.-H., Yen, L.-C., Lin, H.-Y., Hsueh, P.-R. (2008). Increasing Trends in Antimicrobial Resistance among Clinically Important Anaerobes and Bacteroides fragilis Isolates Causing Nosocomial Infections: Emerging Resistance to Carbapenems. Antimicrob. Agents Chemother. 52: 3161-3168 [Abstract] [Full Text]  
  • Bailey, J., Summers, K. M. (2008). Dalbavancin: A new lipoglycopeptide antibiotic. Am J Health Syst Pharm 65: 599-610 [Abstract] [Full Text]  
  • Attwood, R. J., LaPlante, K. L. (2007). Telavancin: A novel lipoglycopeptide antimicrobial agent. Am J Health Syst Pharm 64: 2335-2348 [Abstract] [Full Text]  
  • Huang, Y.-T., Liao, C.-H., Teng, L.-J., Hsueh, P.-R. (2007). Daptomycin Susceptibility of Unusual Gram-Positive Bacteria: Comparison of Results Obtained by the Etest and the Broth Microdilution Method. Antimicrob. Agents Chemother. 51: 1570-1572 [Abstract] [Full Text]  
  • Biedenbach, D. J., Ross, J. E., Fritsche, T. R., Sader, H. S., Jones, R. N. (2007). Activity of Dalbavancin Tested against Staphylococcus spp. and {beta}-Hemolytic Streptococcus spp. Isolated from 52 Geographically Diverse Medical Centers in the United States. J. Clin. Microbiol. 45: 998-1004 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»